Hasil Pencarian - Roland Knoblauch

  • Menampilkan 1 - 4 hasil dari 4
Perbaiki Hasil
  1. 1
    Data on prior pegylated liposomal doxorubicin (PLD) treatment in recurrent ovarian cancer: Post-hoc data analysis from the phase 3 randomized, open-label study comparing trabectedin and PLD versus PLD alone in patients with recurrent ovarian cancer

    Data on prior pegylated liposomal doxorubicin (PLD) treatment in recurrent ovarian cancer: Post-hoc data analysis from the phase 3 randomized, open-label study comparing trabectedi... oleh Bradley J. Monk, Thomas J. Herzog, George Wang, Spyros Triantos, Scott Maul, Roland Knoblauch, Tracy McGowan, Waleed S.W. Shalaby, Robert L. Coleman

    Diterbitkan 2020-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer

    Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer oleh Robin L. Jones, Thomas J. Herzog, Shreyaskumar R. Patel, Margaret von Mehren, Scott M. Schuetze, Brian A. Van Tine, Robert L. Coleman, Roland Knoblauch, Spyros Triantos, Peter Hu, Waleed Shalaby, Tracy McGowan, Bradley J. Monk, George D. Demetri

    Diterbitkan 2021-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Daratumumab Plus Atezolizumab in Previously Treated Advanced or Metastatic NSCLC: Brief Report on a Randomized, Open-Label, Phase 1b/2 Study (LUC2001 JNJ-54767414)

    Daratumumab Plus Atezolizumab in Previously Treated Advanced or Metastatic NSCLC: Brief Report on a Randomized, Open-Label, Phase 1b/2 Study (LUC2001 JNJ-54767414) oleh Rathi N. Pillai, MD, Suresh S. Ramalingam, MD, Meena Thayu, MD, Patricia Lorenzini, RN, Diana A. Alvarez Arias, PhD, Christopher Moy, MS, Natalie Hutnick, PhD, Roland Knoblauch, MD, Huaibao Feng, PhD, Colleen Kane, PhD, Leora Horn, MD, Martin Reck, MD, Santiago Ponce, MD

    Diterbitkan 2021-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor)

    Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor) oleh Charles G Drake, Padmanee Sharma, Sumit K Subudhi, Patricia Troncoso, Sonali Jindal, Sreyashi Basu, Bilal A Siddiqui, Paul G Corn, Shalini S Yadav, Rebecca S S Tidwell, Christopher J Logothetis, Fei Duan, Brian F Chapin, Ai-Di Gu, Alexsandra B Espejo, Michelle Kinder, Curtis A Pettaway, John F Ward, Roland Knoblauch, Natalie Hutnick, Marco Gottardis

    Diterbitkan 2023-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: